Sotera Health (SHC) 주식 개요
소테라 헬스 컴퍼니는 미국, 캐나다, 유럽 및 전 세계의 의료 산업을 위한 멸균 솔루션, 실험실 테스트 및 자문 서비스를 제공합니다. 자세히 보기
SHC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Sotera Health Company 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$18.42 |
| 52주 최고가 | US$19.85 |
| 52주 최저가 | US$10.94 |
| 베타 | 1.77 |
| 1개월 변동 | 13.21% |
| 3개월 변동 | 19.92% |
| 1년 변동 | 56.10% |
| 3년 변동 | -1.76% |
| 5년 변동 | -18.57% |
| IPO 이후 변동 | -26.61% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Jun 25
SHC: Equity Raise And 2026 Earnings Guidance Will Drive Future Upside
The analyst price target for Sotera Health has been nudged higher from $20.13 to about $20.22, reflecting analysts' updated modeling around fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What’s in the News for Sotera Health Sotera Health filed a follow on equity offering of 31,838,253 shares of common stock, classified as a follow on equity offering event.내러티브 업데이트 • Jun 04
SHC: Equity Raise And Higher Guidance Are Expected To Drive Upside
Analysts have maintained their $20.13 price target for Sotera Health, citing only small adjustments in assumptions for discount rate, revenue growth, profit margin and future P/E multiples as the basis for keeping their view steady. What's in the News Sotera Health reported Q1 revenues of $280 million, a 10% year on year increase that came in 3.6% above analyst expectations, alongside growth in adjusted EBITDA and margin expansion, according to recent earnings coverage.Recent updates
내러티브 업데이트 • Jun 25
SHC: Equity Raise And 2026 Earnings Guidance Will Drive Future Upside
The analyst price target for Sotera Health has been nudged higher from $20.13 to about $20.22, reflecting analysts' updated modeling around fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What’s in the News for Sotera Health Sotera Health filed a follow on equity offering of 31,838,253 shares of common stock, classified as a follow on equity offering event.내러티브 업데이트 • Jun 04
SHC: Equity Raise And Higher Guidance Are Expected To Drive Upside
Analysts have maintained their $20.13 price target for Sotera Health, citing only small adjustments in assumptions for discount rate, revenue growth, profit margin and future P/E multiples as the basis for keeping their view steady. What's in the News Sotera Health reported Q1 revenues of $280 million, a 10% year on year increase that came in 3.6% above analyst expectations, alongside growth in adjusted EBITDA and margin expansion, according to recent earnings coverage.분석 기사 • May 13
Sotera Health's (NASDAQ:SHC) Performance Is Even Better Than Its Earnings Suggest
Sotera Health Company ( NASDAQ:SHC ) just reported healthy earnings but the stock price didn't move much. Investors are...내러티브 업데이트 • May 12
SHC: Equity Raise And Reaffirmed 2026 Guidance Will Support Upside
Analysts have trimmed their price target on Sotera Health slightly from $20.50 to $20.13, citing updated assumptions for long term revenue growth, profit margins, and future P/E multiples. What's in the News Sotera Health plans a CEO transition, with Alton Shader set to become CEO and join the board on May 26, 2026.내러티브 업데이트 • Apr 27
SHC: Follow On Equity Raise And 2026 Guidance Will Support Upside
Analysts now see a slightly lower price target for Sotera Health, trimming it from $20.75 to $20.50 as small adjustments to fair value, discount rate, revenue growth, profit margin and forward P/E estimates feed into their updated view. What's in the News Sotera Health completed a follow-on equity offering of 25,000,000 common shares, raising about US$381.75m at a price of US$15.27 per share (Key Developments).내러티브 업데이트 • Apr 10
SHC: Equity Raise And 2026 Revenue Guidance Will Support Future Upside Potential
Analysts have maintained their $20.75 price target on Sotera Health, with only slight model adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions underpinning the updated view. What's in the News Sotera Health completed a follow on equity offering of 25,000,000 common shares, raising about $381.75 million at a price of $15.27 per share (company filing).내러티브 업데이트 • Mar 27
SHC: Equity Raise And 2026 Guidance Will Support Future Upside Potential
Analysts are maintaining a price target of $20.75 for Sotera Health, with only modest tweaks to assumptions such as discount rate, long term revenue growth, profit margin and future P/E multiples, supporting an unchanged valuation view. What's in the News Sotera Health completed a follow on equity offering of 25,000,000 shares of common stock, raising approximately $381.75 million at a price of about $15.27 per share (company filing).내러티브 업데이트 • Mar 10
SHC: Organic Investment And Margin Expansion Will Support Future Upside Potential
Analysts have raised their price target on Sotera Health to $20.75 from $20.44, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that reflect refreshed views on the company’s risk profile and earnings power. What's in the News Sotera Health filed a follow on equity offering of 25,000,000 shares of common stock, and later completed the offering for proceeds of US$381.75m at a price of US$15.27 per share, indicating recent access to equity capital markets.내러티브 업데이트 • Feb 24
SHC: Organic Investment And Deleveraging Will Support Future Upside Potential
Analysts have kept their Sotera Health price target effectively unchanged at about $20.44, reflecting minimal updates to assumptions around the discount rate, long term revenue growth, profit margins, and future P/E expectations. What's in the News Sotera Health signaled that its primary use of capital remains focused on organic growth, with management highlighting continued investment to strengthen existing businesses.Seeking Alpha • Feb 20
Sotera Health: A Predictable And Growing Business
Summary Sotera Health's stock was volatile in 2025 but ultimately finished strong. The core business remains a stable franchise that has consistently grown sales and operating profits with zero down years in the last 20 years. 2025 marked an inflection year, with the core Sterigenics segment posting 10% revenue growth, up from ~4-7% in the previous two years. Read the full article on Seeking Alpha내러티브 업데이트 • Feb 10
SHC: Organic Capital Deployment Will Support Deleveraging And Undervalued Upside
Analysts have maintained their price target for Sotera Health at approximately US$20.44, making only minor adjustments to inputs such as the discount rate, revenue growth, profit margin, and future P/E used in their valuation models. What's in the News Sotera Health signaled it will continue to focus its capital on organic growth initiatives, with CEO Michael Petras highlighting this as the primary use of funds during the JPMorgan Healthcare Conference (Key Developments).내러티브 업데이트 • Jan 26
SHC: Equity Offering And Capital Allocation Priorities Will Guide Balanced Outlook
Analysts have modestly adjusted their price expectations for Sotera Health, with the updated target now at approximately US$20.44. This reflects small tweaks to assumptions such as the discount rate, long-term revenue growth, profit margin and future P/E.
새로운 내러티브 • Jan 24
Bullish View Expects Sterilization Demand And Cobalt 60 Stability To Support Long-Term Upside
Catalysts About Sotera Health Sotera Health provides sterilization services and lab testing that support global health care and medical products. What are the underlying business or industry changes driving this perspective?내러티브 업데이트 • Jan 12
SHC: Follow-On Equity Offering And Lock-Up Terms Will Shape Balanced Outlook
Analysts have lifted their price target for Sotera Health to US$20.44 from US$18.93, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E expectations. What's in the News Sotera Health completed a follow on equity offering of 30,000,000 common shares, raising about US$471 million at a price of US$15.70 per share with a US$0.049 discount per share (Key Developments).분석 기사 • Jan 09
Is Sotera Health Company (NASDAQ:SHC) Potentially Undervalued?
Sotera Health Company ( NASDAQ:SHC ), is not the largest company out there, but it led the NASDAQGS gainers with a...내러티브 업데이트 • Dec 15
SHC: Follow-On Equity Offering Will Drive Bullish Share Performance Next Year
Narrative Update Analysts have modestly raised their price target on Sotera Health, citing fine tuned assumptions around discount rates, revenue growth, margins, and future earnings multiples as justification for a slightly higher implied fair value near $18.93 per share. What's in the News Sotera Health has completed a follow-on equity offering of approximately $471 million, issuing 30 million shares of common stock at about $15.70 per share (Key Developments) The company has filed a separate follow-on equity offering totaling roughly $480.3 million for 30 million shares of common stock, with an indicated price of about $16.01 per share (Key Developments) Executive officers, directors and selling stockholders have agreed to a lock-up on 284,093,929 common shares, restricting most sales and hedging activity from November 6, 2025 to December 7, 2025 (Key Developments) Certain restricted stock units held by insiders are also subject to the same 31-day lock-up period ending December 7, 2025 (Key Developments) Options held by executives, directors and selling stockholders will likewise be restricted during the November 6 to December 7, 2025 lock-up window (Key Developments) Valuation Changes Fair Value: Unchanged at an implied price of approximately $18.93 per share.내러티브 업데이트 • Nov 30
SHC: Follow-On Offering And Lock-Up Expiration Will Shape Shares Next Year
Analysts have maintained their price target for Sotera Health at $18.93, citing consistent expectations for growth and profitability metrics along with minor adjustments to underlying discount rates and projected price-to-earnings ratios. What's in the News Sotera Health Company has completed a Follow-on Equity Offering valued at $471 million, issuing 30 million shares of common stock at $15.70 each (Key Developments).내러티브 업데이트 • Nov 16
SHC: Improved Profit Margins Will Drive Future Share Price Upside
Analysts have raised their price target for Sotera Health from $17.00 to $18.93 per share. They cite an improved profit margin outlook despite slightly lower revenue growth projections.분석 기사 • Nov 11
Sotera Health's (NASDAQ:SHC) Conservative Accounting Might Explain Soft Earnings
The most recent earnings report from Sotera Health Company ( NASDAQ:SHC ) was disappointing for shareholders. However...분석 기사 • Nov 07
Results: Sotera Health Company Beat Earnings Expectations And Analysts Now Have New Forecasts
Sotera Health Company ( NASDAQ:SHC ) investors will be delighted, with the company turning in some strong numbers with...내러티브 업데이트 • Nov 01
SHC: Recent Equity Offerings And Lock-Up Expiry Will Shape Market Outlook
Narrative Update on Sotera Health Analysts have maintained their price target for Sotera Health at $17.00 per share. They cite unchanged growth expectations and financial metrics that support the previous valuation.내러티브 업데이트 • Oct 17
Expanding Sterilization Capacity And EPA Compliance Will Unlock New Markets
Narrative Update: Sotera Health Analyst Price Target Adjustment Analysts have raised their price target for Sotera Health from $16.33 to $17.00 per share. This adjustment reflects a more optimistic outlook based on modest improvements in projected fair value and valuation metrics.내러티브 업데이트 • Oct 03
Expanding Sterilization Capacity And EPA Compliance Will Unlock New Markets
Analysts have modestly raised their price target for Sotera Health from $16.00 to approximately $16.33. This reflects incremental updates in growth and valuation assumptions.분석 기사 • Aug 13
After Leaping 26% Sotera Health Company (NASDAQ:SHC) Shares Are Not Flying Under The Radar
Sotera Health Company ( NASDAQ:SHC ) shareholders would be excited to see that the share price has had a great month...내러티브 업데이트 • Aug 10
Expanding Sterilization Capacity And EPA Compliance Will Unlock New Markets
Sotera Health's consensus price target has increased to $15.75 as analysts reacted positively to a significant rise in net profit margin and a substantial decline in forward P/E, indicating improved profitability and valuation. What's in the News Sotera Health raised full-year 2025 earnings guidance, increasing expected net revenue growth to 4.5%–6.0% from 4.0%–6.0% on a constant currency basis.분석 기사 • Jul 17
These 4 Measures Indicate That Sotera Health (NASDAQ:SHC) Is Using Debt Extensively
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
새로운 내러티브 • Sep 02
Sterigenics' Expansion And Smart Pricing Poised For Sustained Revenue And Margin Growth
Sotera Health's strategic pricing and capacity expansion reflect confidence in maintaining or growing future revenue and net margins, despite economic pressures.주주 수익률
| SHC | US Life Sciences | US 시장 | |
|---|---|---|---|
| 7D | 2.7% | 0.3% | 0.7% |
| 1Y | 56.1% | 16.3% | 20.6% |
수익률 대 산업: SHC은 지난 1년 동안 16.3%의 수익을 기록한 US Life Sciences 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: SHC은 지난 1년 동안 20.6%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| SHC volatility | |
|---|---|
| SHC Average Weekly Movement | 4.2% |
| Life Sciences Industry Average Movement | 9.1% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
안정적인 주가: SHC는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: SHC의 주간 변동성(4%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2015 | 3,000 | Alton Shader | soterahealth.com |
소테라 헬스 컴퍼니는 미국, 캐나다, 유럽 및 전 세계 의료 산업을 위한 멸균 솔루션, 실험실 테스트 및 자문 서비스를 제공합니다. 이 회사는 세 가지 부문으로 운영됩니다: Sterigenics, Nordion, Nelson Labs입니다. Sterigenics 부문은 의료 기기, 제약, 식품 안전 및 고급 애플리케이션 시장에 감마선 조사, 에틸렌 옥사이드 처리, 전자빔 조사 기술을 사용하여 아웃소싱 단말기 멸균 및 조사 서비스를 제공합니다.
Sotera Health Company 기초 지표 요약
| SHC 기초 통계 | |
|---|---|
| 시가총액 | US$5.24b |
| 순이익 (TTM) | US$117.79m |
| 매출 (TTM) | US$1.19b |
44.6x
주가수익비율(P/E)4.4x
주가매출비율(P/S)SHC는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| SHC 손익계산서 (TTM) | |
|---|---|
| 매출 | US$1.19b |
| 매출원가 | US$531.97m |
| 총이익 | US$657.17m |
| 기타 비용 | US$539.38m |
| 순이익 | US$117.79m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | 0.41 |
| 총이익률 | 55.26% |
| 순이익률 | 9.91% |
| 부채/자본 비율 | 343.5% |
SHC의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/07/10 21:50 |
| 종가 | 2026/07/10 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Sotera Health Company는 12명의 분석가가 다루고 있습니다. 이 중 9명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Michael Polark | Baird |
| Luke Sergott | Barclays |
| Sean Dodge | BMO Capital Markets Equity Research |